Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: A magnetic shielding system is provided for a Differential Current Transformer to provide shielding at multiple locations for a circuit braker. It comprises an outer shield being cylindrically-shaped and closely fitting and an inner shield being closely fitting over four conductor cables that pass through the Differential Current Transformer. An inside diameter of the inner shield is less than 1.5 times the diameter of the smallest circle that can enclose the four conductor cables that pass through the Differential Current Transformer. In an axial direction, the magnetic shielding system comprises multiple layers of flat, washer-shaped parts in which at least one layer on top and one layer on bottom is of magnetic shielding material. Magnetic shielding is provided at the multiple locations using two or more different classes of materials.

Abstract: A solid-state circuit breaker comprises an air gap, at least one counter and/or a timer, a memory, a radio and a microprocessor to: retrieve saved health data, alert data and counter, timer data from the memory, determine a status of a heath rating by data and comparing the heath rating to a threshold, if it is poor, send a message via a smart phone application (APP) and start a counter or timer, determine if the counter is at a predefined value and/or the timer is expired, if the counter is at a predefined value and/or the timer is expired, turn OFF the breaker and inhibit from being turned on, send a breaker OFF/disabled alert message using the radio to an end user/a customer via the APP, and if the counter is not at a predefined value and/or the timer is not expired, increment/decrement the counter and/or the timer.

Abstract: Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

Abstract: Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

Abstract: The invention relates methods of determining therapeutic doses for conditions mediated by integrin and methods of therapy for conditions mediated by integrin comprising administering an integrin modulating compound in an amount that achieves receptor occupancy of the integrin. The invention further relates to dosage forms for daily administration of integrin modulating compounds that are useful for treating conditions mediated by at least one integrin including, e.g., fibrosis such as idiopathic pulmonary fibrosis (IFF) and nonspecific interstitial pneumonia (NSIP).

Abstract: The invention relates to methods of (i) treating a subject for a disease, (ii) amelioration of decline of forced vital capacity in a subject in need thereof, (iii) modulating ?V?6 integrin, ?V?1 integrin, or both ?V?6 integrin and ?V?1 integrin in a subject in need thereof, (iv) increasing the expression of one or more genes in a subject in need thereof, (v) decreasing the expression of one or more genes in a subject in need thereof, and (vi) modulating the activity of at least one gene affecting fibrotic activity in a subject in need thereof, comprising administration of compounds of Formula (A), Formula (I), Formula (II), or (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein; and administering to the subject at least a second drug selected from pirfenidone and nintedanib, or a salt thereof.

Abstract: A portable temperature-controlled container for receiving and housing one or more handheld carriers, each handheld carrier configured to transfer samples to and from a temperature-controlled storage environment, the handheld carrier including a handle and a tray portion, the tray portion configured to be slid into a port of a rack or tower provided in the temperature-controlled storage environment in order to withdraw a sample located in the port, the portable temperature-controlled container including a housing having an opening forming an internal cavity configured to receive one or more handheld carriers, and a lid configured to substantially close the opening, where the housing includes a recess configured to receive the handle of the handheld carrier such that closing of the lid substantially seals the internal cavity when the one or more handheld carriers are placed in the housing.

Abstract: A power tool comprises an adjustable auxiliary handle assembly that facilities safe use of the tool by the operator while allowing convenient carry and storage of the tool when not in use. The adjustable auxiliary handle assembly comprises an indexing mechanism that includes an angled connector, a slidable latching mechanism and a handle base. The indexing mechanism allows a longitudinal handle to rotate and be locked in a position convenient and comfortable to the operator. The indexing mechanism is adjustable and can be operated with one hand (e.g., one-handed operation). The latching mechanism holds the auxiliary handle position in place while allowing the power tool to be used in high-torque/high load applications.

Abstract: An electric tool is provided with a second switch that is actuated in order for the tool to be used. The second switch is on a second handle that is grasped by the operator with a different hand than the hand that actuates the main trigger switch. Communication between the second switch and the tool occurs with a wireless signal indicating that the second switch has been actuated.

Abstract: A cooling assembly for a power tool includes an air mover configured to be disposed within a housing assembly at a first end of a generally longitudinal enclosure proximate to a handle enclosure. The air mover is configured to direct air into the housing assembly and then generally perpendicularly to a longitudinally extending direction of the generally longitudinal enclosure. The cooling assembly also includes a duct configured to connect to the air mover and be in fluid communication with the air mover to direct air into the handle enclosure. The duct includes an inflow segment defining a first area for receiving the air from the air mover, an outflow segment defining a second area for directing the air from the air mover into the handle enclosure, and a connecting segment connecting the inflow segment to the outflow segment.

Abstract: A portable temperature-controlled container for receiving and housing one or more handheld carriers, each handheld carrier configured to transfer samples to and from a temperature-controlled storage environment, the handheld carrier including a handle and a tray portion, the tray portion configured to be slid into a port of a rack or tower provided in the temperature-controlled storage environment in order to withdraw a sample located in the port, the portable temperature-controlled container including a housing having an opening forming an internal cavity configured to receive one or more handheld carriers, and a lid configured to substantially close the opening, where the housing includes a recess configured to receive the handle of the handheld carrier such that closing of the lid substantially seals the internal cavity when the one or more handheld carriers are placed in the housing.

Abstract: The invention relates to methods of therapy using compounds of formula (I) and formula (II): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (II) and pharmaceutical compositions thereof are integrin inhibitors that are useful in therapy for a condition, for example, caused by or associated with an infectious agent, shock, pancreatitis, or trauma. The condition can include one or more of pulmonary fibrosis associated with rheumatoid arthritis or progressive familial intrahepatic cholestasis (PFIC).

Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: A system is provided for transporting, handling and monitoring samples in a temperature-controlled storage environment. The system includes a handheld carrier configured to transfer samples to and from a temperature-controlled storage station and a temperature-controlled container for receiving and housing one or more carriers. The carrier includes an integrated sample identification and temperature sensing capability configured to monitor a thermal history of one or more samples during transport, handling and storage including as the samples are conveyed between the temperature-controlled storage environment and the temperature-controlled container. That is, the carrier is adapted to be held in the hand during use. A carrier for conveying and monitoring samples during transport, handling and storage is also provided.

Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: A device for indicating violation of a temperature limit of an item is provided. The device is positionable near the item and includes a sensor configured to change its state permanently when the temperature limit is violated. The change in sensor state is machine-readable to provide a permanent indication of the temperature limit violation. The sensor includes a reservoir for storing a fluid that changes phase from a solid to a liquid when the temperature limit is violated and a channel in fluid communication with the reservoir for receiving flow of the fluid in liquid phase from the reservoir. The sensor is arranged to allow flow of the fluid in the liquid phase such that the state of the sensor is permanently changed. The sensor is further configured to prevent the fluid flow from permanently changing the sensor state until activation of the sensor from a resting state. A system and method for detecting violation of a temperature limit of an item using the device is also provided.

Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: A cooling assembly for a power tool includes an air mover configured to be disposed within a housing assembly at a first end of a generally longitudinal enclosure proximate to a handle enclosure. The air mover is configured to direct air into the housing assembly and then generally perpendicularly to a longitudinally extending direction of the generally longitudinal enclosure. The cooling assembly also includes a duct configured to connect to the air mover and be in fluid communication with the air mover to direct air into the handle enclosure. The duct includes an inflow segment defining a first area for receiving the air from the air mover, an outflow segment defining a second area for directing the air from the air mover into the handle enclosure, and a connecting segment connecting the inflow segment to the outflow segment.

Abstract: Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.